Replies to post #17 on Aegerion Pharmaceuticals Inc (fka AEGR)

[surf1944]

7:01AM Aegerion Pharma announces issuance of patent by European Patent Office (AEGR) 20.37 : Co announced the issuance by the European Patent Office of Patent No. EP1725234 for a method of treating hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia, using step-wise, increasing doses of lomitapide. The patent expires in 2025. Aegerion's New Drug Application for lomitapide is under review by the FDA and its Marketing Authorization Application for lomitapide is under review by the European Medicines Agency. Aegerion is seeking approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with homozygous familial hypercholesterolemia